Wireless glucose sensors could transform ICU care — but can they deliver?

NCT ID NCT07769138

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This study tests whether continuous glucose monitors (CGMs) like the Dexcom G7 can be safely and effectively used in intensive care units. The monitors provide real-time blood sugar readings and alarms for dangerously high or low levels, potentially reducing the need for frequent finger-prick tests. Researchers will track how many eligible patients agree to participate, how quickly monitoring starts, and how often the devices fail or cause issues. The goal is to see if this technology is practical for routine ICU use, not to measure its impact on patient outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Dexcom G7 continuous glucose monitor with ViewsEMR telemetry
What this could lead to
If successful, this could make continuous glucose monitoring a standard, safe tool in intensive care, potentially reducing dangerous blood sugar swings in critically ill patients.
What could go wrong
This is a small, early observational study focused on feasibility, not outcomes. It may not prove clinical benefit, and device issues or skin reactions could limit use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTINUOUS GLUCOSE MONITORING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Imperial College Healthcare NHS Trust

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.